請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62562
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃敏銓 | |
dc.contributor.author | Wei-Jen Wang | en |
dc.contributor.author | 王韋人 | zh_TW |
dc.date.accessioned | 2021-06-16T16:04:29Z | - |
dc.date.available | 2016-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-06-26 | |
dc.identifier.citation | 1. Jemal A, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61(2):69-90.
2. Volk ML, Hernandez JC, Su GL, Lok AS, & Marrero JA (2007) Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer biomarkers : section A of Disease markers 3(2):79-87. 3. Altekruse SF, McGlynn KA, & Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(9):1485-1491. 4. Arey BJ (2012) The Role of Glycosylation in Receptor Signaling. 5. Varki A CR, Esko JD, et al. (2009) Essentials of Glycobiology. 2nd edition. (Cold Spring Harbor Laboratory Press, New York). 6. Van den Steen P, Rudd PM, Dwek RA, & Opdenakker G (1998) Concepts and principles of O-linked glycosylation. Critical reviews in biochemistry and molecular biology 33(3):151-208. 7. Gill DJ, Clausen H, & Bard F (2011) Location, location, location: new insights into O-GalNAc protein glycosylation. Trends in Cell Biology 21(3):149-158. 8. Coutinho PM, Deleury E, Davies GJ, & Henrissat B (2003) An evolving hierarchical family classification for glycosyltransferases. Journal of molecular biology 328(2):307-317. 9. Mitra N, Sinha S, Ramya TN, & Surolia A (2006) N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends in biochemical sciences 31(3):156-163. 10. Hennet T (2012) Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochimica et biophysica acta 1820(9):1306-1317. 11. Thiel C & Korner C (2013) Therapies and therapeutic approaches in Congenital Disorders of Glycosylation. Glycoconjugate journal 30(1):77-84. 12. Ohtsubo K & Marth JD (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126(5):855-867. 13. Tian E & Ten Hagen KG (2009) Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconjugate journal 26(3):325-334. 14. Ju T, Otto VI, & Cummings RD (2011) The Tn antigen-structural simplicity and biological complexity. Angewandte Chemie (International ed. in English) 50(8):1770-1791. 15. Ten Hagen KG, Fritz TA, & Tabak LA (2003) All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13(1):1R-16R. 16. Tarp MA & Clausen H (2008) Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochimica et biophysica acta 1780(3):546-563. 17. Pratt MR, et al. (2004) Deconvoluting the functions of polypeptide N-alpha-acetylgalactosaminyltransferase family members by glycopeptide substrate profiling. Chemistry & biology 11(7):1009-1016. 18. Ten Hagen KG, et al. (1999) Characterization of a UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase that displays glycopeptide N-acetylgalactosaminyltransferase activity. The Journal of biological chemistry 274(39):27867-27874. 19. Tsuboi S, Hatakeyama S, Ohyama C, & Fukuda M (2012) Two opposing roles of O-glycans in tumor metastasis. Trends in molecular medicine 18(4):224-232. 20. Fu J, et al. (2008) Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. The Journal of clinical investigation 118(11):3725-3737. 21. Xia L, et al. (2004) Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. The Journal of cell biology 164(3):451-459. 22. Ju T & Cummings RD (2002) A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proceedings of the National Academy of Sciences of the United States of America 99(26):16613-16618. 23. Narimatsu Y, et al. (2008) Immunocytochemical analysis for intracellular dynamics of C1GalT associated with molecular chaperone, Cosmc. Biochemical and biophysical research communications 366(1):199-205. 24. Fukuda M (2006) Roles of mucin-type O-glycans synthesized by core2beta1,6-N-acetylglucosaminyltransferase. Methods in enzymology 416:332-346. 25. Nakayama J, et al. (1999) Expression cloning of a human alpha1, 4-N-acetylglucosaminyltransferase that forms GlcNAcalpha1-->4Galbeta-->R, a glycan specifically expressed in the gastric gland mucous cell-type mucin. Proceedings of the National Academy of Sciences of the United States of America 96(16):8991-8996. 26. Schwientek T, et al. (1999) Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. The Journal of biological chemistry 274(8):4504-4512. 27. Iwai T, et al. (2002) Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans. The Journal of biological chemistry 277(15):12802-12809. 28. Cazet A, Julien S, Bobowski M, Burchell J, & Delannoy P (2010) Tumour-associated carbohydrate antigens in breast cancer. Breast cancer research : BCR 12(3):204. 29. Kim YS, Gum J, Jr., & Brockhausen I (1996) Mucin glycoproteins in neoplasia. Glycoconjugate journal 13(5):693-707. 30. Cao Y, Stosiek P, Springer GF, & Karsten U (1996) Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochemistry and cell biology 106(2):197-207. 31. Park JH, et al. (2010) Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res 70(7):2759-2769. 32. Iwai T, et al. (2005) Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 102(12):4572-4577. 33. Brockhausen I (2006) Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO reports 7(6):599-604. 34. Springer GF (1997) Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. Journal of molecular medicine (Berlin, Germany) 75(8):594-602. 35. Wang BL, Springer GF, & Carlstedt SC (1997) Quantitative computerized image analysis of Tn and T (Thomsen-Friedenreich) epitopes in prognostication of human breast carcinoma. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 45(10):1393-1400. 36. Kawaguchi T, et al. (2006) Expression of Vicia villosa agglutinin (VVA)-binding glycoprotein in primary breast cancer cells in relation to lymphatic metastasis: is atypical MUC1 bearing Tn antigen a receptor of VVA? Breast cancer research and treatment 98(1):31-43. 37. Fernandez Madrid F, Tang N, Alansari H, Karvonen RL, & Tomkiel JE (2005) Improved approach to identify cancer-associated autoantigens. Autoimmunity reviews 4(4):230-235. 38. Laack E, et al. (2002) Lectin histochemistry of resected adenocarcinoma of the lung: helix pomatia agglutinin binding is an independent prognostic factor. The American journal of pathology 160(3):1001-1008. 39. Kakeji Y, Tsujitani S, Mori M, Maehara Y, & Sugimachi K (1991) Helix pomatia agglutinin binding activity is a predictor of survival time for patients with gastric carcinoma. Cancer 68(11):2438-2442. 40. Konno A, Hoshino Y, Terashima S, Motoki R, & Kawaguchi T (2002) Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis. Clinical & experimental metastasis 19(1):61-70. 41. Eisele JL, Tello D, Osinaga E, Roseto A, & Alzari PM (1993) Crystallization and preliminary crystallographic analysis of a tetrameric isolectin from Vicia villosa, specific for the Tn antigen. Journal of molecular biology 230(2):670-672. 42. Tollefsen SE & Kornfeld R (1983) Isolation and characterization of lectins from Vicia villosa. Two distinct carbohydrate binding activities are present in seed extracts. The Journal of biological chemistry 258(8):5165-5171. 43. Piller V, Piller F, & Cartron J-P (1990) Comparison of the carbohydrate-binding specificities of seven N-acetyl-D-galactosamine-recognizing lectins. European Journal of Biochemistry 191(2):461-466. 44. Puri KD, Gopalakrishnan B, & Surolia A (1992) Carbohydrate binding specificity of the Tn-antigen binding lectin from Vicia villosa seeds (VVLB4). FEBS Lett 312(2-3):208-212. 45. Kono M, et al. (2000) Redefined substrate specificity of ST6GalNAc II: a second candidate sialyl-Tn synthase. Biochemical and biophysical research communications 272(1):94-97. 46. Marcos NT, et al. (2011) ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Frontiers in bioscience (Elite edition) 3:1443-1455. 47. Julien S, Videira PA, & Delannoy P (2012) Sialyl-Tn in Cancer: (How) Did We Miss the Target? Biomolecules 2(4):435-466. 48. Kakeji Y, et al. (1995) Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma. British journal of cancer 71(1):191-195. 49. Victorzon M, Nordling S, Nilsson O, Roberts PJ, & Haglund C (1996) Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer. International journal of cancer. Journal international du cancer 65(3):295-300. 50. Imada T, et al. (1999) Sialyl Tn antigen expression is associated with the prognosis of patients with advanced colorectal cancer. Hepato-gastroenterology 46(25):208-214. 51. Ghazizadeh M, Ogawa H, Sasaki Y, Araki T, & Aihara K (1997) Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis. Human pathology 28(8):960-966. 52. Glinskii OV, et al. (2012) Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. Neoplasia (New York, N.Y.) 14(1):65-73. 53. Khaldoyanidi SK, et al. (2003) MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. The Journal of biological chemistry 278(6):4127-4134. 54. Blomme B, Van Steenkiste C, Callewaert N, & Van Vlierberghe H (2009) Alteration of protein glycosylation in liver diseases. Journal of Hepatology 50(3):592-603. 55. el-Houseini ME, et al. (2005) Enhanced detection of hepatocellular carcinoma. Cancer control : journal of the Moffitt Cancer Center 12(4):248-253. 56. Shiraki K, et al. (1995) A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology (Baltimore, Md.) 22(3):802-807. 57. Li D, Mallory T, & Satomura S (2001) AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clinica Chimica Acta 313(1–2):15-19. 58. Sasaki M, Yamato T, & Nakanuma Y (1999) Expression of sialyl-Tn, Tn and T antigens in primary liver cancer. Pathology international 49(4):325-331. 59. Cao Y, Karsten U, Otto G, & Bannasch P (1999) Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Archiv : an international journal of pathology 434(6):503-509. 60. Hennebicq-Reig S, et al. (1998) Permanent exposure of mucin-secreting HT-29 cells to benzyl-N-acetyl-alpha-D-galactosaminide induces abnormal O-glycosylation of mucins and inhibits constitutive and stimulated MUC5AC secretion. The Biochemical journal 334 ( Pt 1):283-295. 61. Marcos NT, et al. (2004) Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 64(19):7050-7057. 62. Harduin-Lepers A, et al. (2000) Cloning, expression and gene organization of a human Neu5Ac alpha 2-3Gal beta 1-3GalNAc alpha 2,6-sialyltransferase: hST6GalNAcIV. The Biochemical journal 352 Pt 1:37-48. 63. Harduin-Lepers A, et al. (2001) The human sialyltransferase family. Biochimie 83(8):727-737. 64. Schwientek T, et al. (2000) Control of O-glycan branch formation. Molecular cloning and characterization of a novel thymus-associated core 2 beta1, 6-n-acetylglucosaminyltransferase. The Journal of biological chemistry 275(15):11106-11113. 65. Bierhuizen MF, Maemura K, & Fukuda M (1994) Expression of a differentiation antigen and poly-N-acetyllactosaminyl O-glycans directed by a cloned core 2 beta-1,6-N-acetylglucosaminyltransferase. The Journal of biological chemistry 269(6):4473-4479. 66. Yeh J-C, et al. (2001) Novel Sulfated Lymphocyte Homing Receptors and Their Control by a Core1 Extension β1,3-N-Acetylglucosaminyltransferase. Cell 105(7):957-969. 67. Itzkowitz SH, et al. (1990) Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66(9):1960-1966. 68. Ohno S, et al. (2006) Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis. Anticancer research 26(6A):4047-4053. 69. Hamada S-i, Furumoto H, Kamada M, Hirao T, & Aono T (1993) High expresion rate of Tn antigen in metastatic lesions of uterine cervical cancers. Cancer Letters 74(3):167-173. 70. Wu AM, et al. (2008) Differential contributions of recognition factors of two plant lectins -Amaranthus caudatus lectin and Arachis hypogea agglutinin, reacting with Thomsen-Friedenreich disaccharide (Galbeta1-3GalNAcalpha1-Ser/Thr). Biochimie 90(11-12):1769-1780. 71. Bard F, Mazelin L, Pechoux-Longin C, Malhotra V, & Jurdic P (2003) Src regulates Golgi structure and KDEL receptor-dependent retrograde transport to the endoplasmic reticulum. The Journal of biological chemistry 278(47):46601-46606. 72. Gill DJ, Chia J, Senewiratne J, & Bard F (2010) Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. The Journal of cell biology 189(5):843-858. 73. Gerken TA, Owens CL, & Pasumarthy M (1998) Site-specific core 1 O-glycosylation pattern of the porcine submaxillary gland mucin tandem repeat. Evidence for the modulation of glycan length by peptide sequence. The Journal of biological chemistry 273(41):26580-26588. 74. Brockhausen I, Dowler T, & Paulsen H (2009) Site directed processing: role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2. Biochimica et biophysica acta 1790(10):1244-1257. 75. Ito Y, et al. (2001) Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. J Hepatol 35(1):68-73. 76. Lau GM, et al. (2009) Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Digestive diseases and sciences 54(7):1465-1474. 77. Danussi C, et al. (2009) A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction. Glycobiology 19(10):1056-1067. 78. Slovin SF, et al. (2003) Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21(23):4292-4298. 79. Ragupathi G, et al. (2006) Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. Journal of the American Chemical Society 128(8):2715-2725. 80. Astronomo RD & Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nature reviews. Drug discovery 9(4):308-324. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62562 | - |
dc.description.abstract | 異常的醣化作用是癌細胞常見的一種特徵。腫瘤相關醣抗原─Tn、sialyl-Tn、T和sialyl-T抗原,是由於不正常的黏蛋白型O-聚醣醣化作用所導致。這些腫瘤相關黏蛋白型O-聚醣的表現通常與許多癌症的惡性程度以及預後有直接的相關性。曾有研究指出在肝癌中有腫瘤相關黏蛋白型O-聚醣的表現;然而,這些醣抗原與肝癌的臨床病理特性以及預後之間的關聯性仍不明確。在本篇研究中,我們利用免疫組織化學染色法檢視Tn、sialyl-Tn、T和sialyl-T抗原的在肝癌組織中的表現情形。結果顯示,有76% (69/91)、 58% (29/50)、 26% (13/50)和26% (13/50)的肝癌組織分別表現Tn、sialyl-Tn、T和sialyl-T抗原。其中,Tn抗原的表現和肝癌的腫瘤的大小和侵犯程度(T stage, p < 0.005)、組織分化程度(histological grade, p = 0.001)、有無血管侵襲(vascular invasion, p = 0.001)以及是否復發(recurrence, p < 0.05)都有統計上的正相關。有較高Tn抗原表現的病人,其五年存活率也較差(p < 0.05)。此外,我們也檢視了負責合成黏蛋白型O-聚醣的酵素的mRNA的表現量,包含有GALNTs、ST6GALNACs、ST3GALs、C1GALT1、COSMC、GCNTs、B3GNT3和B3GNT6等幾個酵素家族。結果顯示,GALNT10、ST6GALNAC2和C1GALT1的mRNA表現量在肝癌中有顯著的上升;相反的,GALNT2、ST3GAL1和B3GNT6的mRNA表現量在肝癌中有顯著的下降。此結果顯示,在肝癌病人中不正常的醣化基因的表現,可能是導致異常黏蛋白型O-聚醣表現的原因之一。總結來說,本研究發現在肝癌病人中有不正常Tn、sialyl-Tn、T和sialyl-T抗原;而其中Tn抗原的表現量與肝癌的惡性程度以及預後有顯著的相關。根據這些結果我們推測,異常黏液型O-聚醣的表現以及與其合成相關的醣類基因,在肝癌的發展中可能扮演著重要的角色。 | zh_TW |
dc.description.abstract | Altered glycosylation is a common feature of cancer cells. Expressions of Tn, sialyl-Tn, T, and sialyl-T antigens are caused by aberrant mucin-type O-glycosylation. These antigens are tumor-associated carbohydrate antigens, and their expressions are often associated with malignant properties and clinical outcome of many cancers. Although the expressions of these antigens in hepatocellular carcinoma (HCC) have been reported, the correlation between their expressions and clinicapathological features and prognosis is still unclear. In this study, immunohistochemistry showed that the prevalence of Tn, sialyl-Tn, T, and sialyl-T antigens in human HCC tissues was 76% (69/91), 58% (29/50), 26% (13/50), and 26% (13/50), respectively. The expression level of Tn antigens was positively associated with advanced T stage (p < 0.005) and higher histological grade (p = 0.001), as well as increased vascular invasion (p = 0.001) and recurrence (p < 0.05) of HCC. In addition, high expression of Tn antigens significantly correlated with poor 5-year survival of HCC patients (p < 0.05). Furthermore, we analyzed the mRNA expression of glycogenes for O-glycan synthesis, including GALNTs, ST6GALNACs, ST3GALs, C1GALT1, COSMC, GCNTs, B3GNT3, and B3GNT6, in human HCC tissues by real-time RT-PCR. Among them, the mRNA levels of GALNT10, ST6GALNAC2, and C1GALT1 were significantly up-regulated, while GALNT2, ST3GAL1, and B3GNT6 were significantly down-regulated in HCC tissues compared with those in the non-tumor part. These results suggest that the expression of aberrant O-glycans in HCC may be resulted from the dysregulation of these glycogenes. In conclusion, our findings suggest that Tn, sialyl-Tn, T, and sialyl-T antigens are expressed in HCC, and the expression of Tn antigens is associated with poor prognosis of HCC patients. These results imply that mucin-type O-glycans and O-glycogenes may play roles in modulating tumor progression of HCC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:04:29Z (GMT). No. of bitstreams: 1 ntu-102-R00446002-1.pdf: 2284956 bytes, checksum: 3711b660eae1262eb1a78b0ca3aab831 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 口試委員會審定書 #
誌謝 i 摘要 ii ABSTRACT iii CONTENTS iv LIST OF FIGURES vii LIST OF TABLES ix Chapter 1 Introduction 1 1.1 General introduction to hepatocellular carcinoma 1 1.2 Protein glycosylation 1 1.3 Mucin type O-glycosylation 2 1.4 Mucin-type O-glycans in cancer 4 1.5 Altered glycosylation in HCC 6 Chapter 2 Specific Aims 7 Chapter 3 Material and Methods 8 3.1 Patients, clinical samples and tissue array 8 3.2 Cell lines and cell culture 8 3.3 Lectins 9 3.4 Flow cytometric analysis 9 3.5 Immunohistochemistry 10 3.6 Scoring of Immunohistochemistry Analysis 11 3.7 Reverse transcription polymerase chain reaction (RT-PCR) 11 3.8 Quantitative real-time PCR analysis 12 3.9 Knockdown of GALNT10 expression 12 3.10 Western Blotting 12 3.11 Statistical Analysis 13 Chapter 4 Results 14 4.1 Lectin VVA and PNA could discriminate the subtle changes of Tn and T antigens respectively 14 4.2 Tn and sialyl-Tn antigens were expressed in human HCC cell lines 14 4.3 T and sialyl-T antigens were expressed in human HCC cell lines 15 4.4 Patient population and tumor characteristics 15 4.5 Tn antigens are frequently overexpressed in human HCC 16 4.6 Expression of sialyl-Tn antigens in human HCC 16 4.7 Expression of T antigens in human HCC 17 4.8 Expression of sialyl-T antigens in human HCC 17 4.9 Expression level of Tn antigens is associated with the clinicopathological feature of HCC 18 4.10 Expression level of sialy-Tn, T, and sialyl-T antigens is not associated with the clinicopathological feature of HCC 19 4.11 High Tn antigens expression is associated with poor survival of HCC. 19 4.12 Expression of T antigen is not associated with the survival of HCC 20 4.13 mRNA expression of GALNT2 is down-regulated and GALNT10 is up-regulated in HCC tissues by QPCR analysis 20 4.14 mRNA expression of ST6GALNAC2 is up-regulated in HCC tissues by QPCR analysis 21 4.15 mRNA expression of C1GALT1 is up-regulated in HCC tissues by QPCR analysis 21 4.16 mRNA expression of ST3GAL1 and ST3GAL6 is down-regulated in HCC tissues by QPCR analysis 21 4.17 There is no significant change in GCNT1, 3, and 4 mRNA level in paired HCC tissues by QPCR analysis 22 4.18 There is no significant change in B3GNT3 mRNA level in paired HCC tissues by QPCR analysis 22 4.19 mRNA expression of B3GNT6 is down-regulated in HCC tissues by QPCR analysis 23 4.20 Expression of glycogenes which modulate mucin-type O-glycans in HCC cell lines 23 4.21 Knockdown of GALNT10 decreases binding of VVA to glycoproteins 23 Chapter 5 Discussion 25 REFERENCES 30 | |
dc.language.iso | en | |
dc.title | 黏蛋白型O-聚醣在肝癌中的表現情形 | zh_TW |
dc.title | Expression of mucin-type O-glycans in hepatocellular carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳耀銘,賴逸儒 | |
dc.subject.keyword | O-型醣化作用,黏蛋白型O-聚醣,肝癌,Tn抗原, | zh_TW |
dc.subject.keyword | O-glycosylation,mucin-type O-glycan,Tn antigen,HCC, | en |
dc.relation.page | 73 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-06-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨生物細胞學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 2.23 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。